Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges

Human mesenchymal stem cell (hMSC)-based therapies are of increasing interest in the field of regenerative medicine. As economic considerations have shown, allogeneic therapy seems to be the most cost-effective method. Standardized procedures based on instrumented single-use bioreactors have been sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Jossen, Valentin, van den Bos, Christian, Eibl, Regine, Eibl, Dieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Mini-Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895685/
https://www.ncbi.nlm.nih.gov/pubmed/29564526
http://dx.doi.org/10.1007/s00253-018-8912-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895685/
https://www.ncbi.nlm.nih.gov/pubmed/29564526
http://dx.doi.org/10.1007/s00253-018-8912-x

Ejemplares similares